Quantifying the treatment efficacy of reverse transcriptase inhibitors: New analyses of clinical data based on within-host modeling

BMC Public Health

Volumn 9, Issue SUPPL. 1, 2009, Pages

  Breban, Romulus ^a,b   Napravnik, Sonia ^c   Kahn, James ^d   Blower, Sally ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BASIC REPRODUCTION NUMBER; CD4 LYMPHOCYTE COUNT; CLINICAL DECISION MAKING; DRUG EFFICACY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CODING; VIRION; VIRUS LOAD; VIRUS REPLICATION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECONOMICS; FEMALE; IMMUNOLOGY; MALE; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 72749127632     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-9-S1-S11     Document Type: Article

References (39)

1. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. SM Hammer JJ Eron Jr P Reiss RT Schooley MA Thompson S Walmsley P Cahn MA Fischl JM Gatell MS Hirsch, et al. JAMA 2008 300 5 555 570
2. Modelling viral and immune system dynamics. AS Perelson, Nat Rev Immuniol 2002 2 28 36
3. HIV-1 Dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. AS Perelson AU Neumann M Markowitz JM Leonard DD Ho, Science 1996 271 1582 1586
4. MA Nowak MM Robert, Virus dynamics: mathematical principles of immunology and virology Oxford: Oxford University Press 2000
5. Virus dynamics of immune responses to persistent viruses. S Bonhoeffer RM May GM Shaw MA Nowak, Proc Natl Acad Sci USA 1997 94 6971 6976
6. Human immunodeficiency virus drug therapy and viral load. S Bonhoeffer J Coffin MA Nowak, J Virol 1997 71 4 3275 3278
7. Dynamics of immune escape during HIV/SIV infection. CL Althaus RJ De Boer, PLoS Comput Biol 2008 4 7 1000103
8. D Wodarz, Killer Cell Dynamics: Mathematical and Computational Approaches to Immunology New York: Springer Verlag 2006
9. Dynamics of recurrent viral infection. W Yao L Hertel LM Wahl, Proc Biol Sci 2006 273 1598 2193 2199
10. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. L Rong AS Perelson, Math Biosci 2008
11. Dynamics of HIV-Infection of Cd4+ T-cells. AS Perelson DE Kirschner R Deboer, Math Biosci 1993 114 1 81 125
12. T-cell induced pathogenesis in HIV: bystander effects and latent infection. DC Krakauer M Nowak, Proc R Soc Lond B Biol Sci 1999 266 1423 1069 1075
13. A delay-differential equation model of HIV infection of CD4(+) T-cells. RV Culshaw SG Ruan, Math Biosci 2000 165 1 27 39
14. Virus dynamics and drug therapy. S Bonhoeffer RM May GM Shaw MA Nowak, Proc Natl Acad Sci USA 1997 94 6971 6976
15. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? RJ Smith, Proc R Soc B 2006 273 1586 617 624
16. Adherence and drug resistance: predictions for therapy outcome. LM Wahl MA Nowak, Proc R Soc Lond B Biol Sci 2000 267 1445 835 843
17. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. DJ Austin NJ White RM Anderson, J Theor Biol 1998 194 313 339
18. Short and long period optimization of drug doses in the treatment of AIDS. MA Caetano T Yoneyama, An Acad Bras Cienc 2002 74 3 379 392
19. Optimization of HAART with genetic algorithms and agent-based models of HIV infection. F Castiglione F Pappalardo M Bernaschi S Motta, Bioinformatics 2007 23 24 3350 3355
20. Optimal drug treatment regimens for HIV depend on adherence. O Krakovska LM Wahl, J Theor Biol 2007 246 3 499 509
21. Role of parametric resonance in virological failure during HIV treatment interruption therapy. R Breban S Blower, Lancet 2006 367 9518 1285 1289
22. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? KS Dorman AH Kaplan K Lange JS Sinsheimer, J Acquir Immune Defic Syndr 2000 25 5 398 402
23. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting". O Krakovska LM Wahl, Bull Math Biol 2007 69 8 2627 2647
24. Immune responses and the emergence of drug-resistant virus strains in vivo. D Wodarz AL Lloyd, Proc Biol Sci 2004 271 1544 1101 1109
25. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. RJ Smith LM Wahl, Bull Math Biol 2005 67 4 783 813
26. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drugresistance. H Wu Y Huang EP Acosta SL Rosenkranz DR Kuritzkes JJ Eron AS Perelson JG Gerber, J Acquir Immune Defic Syndr 2005 39 3 272 283
27. Glancing behind virus load variation in HIV-1 infection. S Bonhoeffer G Funk H Gunthard M Fischer V Muller, TRENDS in Microbiology 2003 11 11 499 504
28. Efavirenz plus zidovudine and lamivudine, evafirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. S Staszewski J Morales-Ramirez KT Tashima A Rachlis D Skies J Stanford R Stryker P Johnson DF Labriola D Farina, et al. N Engl J Med 1999 341 25 1865 1872
29. RM Anderson RM May, Infectious diseases of humans Oxford: Oxford University Press 1992
30. Strong approximations for epidemic models. F Ball P Donnelly, Stochastic Processes and Applications 1995 55 1 21
31. Stochastic Processes in Epidemiology. C Mode C Sleeman, Singapore: World Scientific 2003
32. Nature of equilibria and effects of drug treatments in some simple viral population dynamical models. HC Tuckwell FYM Wan, IMA J Math Appl Med Biol 2000 17 4 311 327
33. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. GA Funk M Fischer B Joos M Opravil HF Gunthard B Ledergerber S Bonhoeffer, J Acquir Immune Defic Syndr 2001 26 5 397 404
34. Improving estimates of the basic reproductive ratio: Using both the mean and the dispersal of transition times. JM Heffernan LM Wahl, Theor Pop Biol 2006 70 2 135 145
35. Antiretroviral price list. Clinton Foundation HIV/AIDS Initiative 2008
36. Clinton Foundation HIV/AIDS Initiative. http://www.clintonfoundation.org/ what-we-do/clinton-hiv-aids-initiative
37. Procurement Consortium List (September 2008). Clinton HIV/AIDS Initiative 2008
38. Untangling the web of antiretroviral price reductions, 11 edn. Médecins Sans Frontières 2008
39. The power of partnerships: The president's emergency plan for AIDS relief (PEPFAR). Office of the United States Global AIDS Coordinator 2007